Drug Repurposing News and Research

RSS

Northwestern’s SPORE has made advances in understanding the genetic basis of glioblastoma

Glioblastoma is one of the deadliest cancers known to man. While the advent of immunotherapy and other cutting-edge treatments have prolonged life for people afflicted with other types of cancer, the prognosis for glioblastoma has remained relatively constant: just 18 months.

3 Oct 2021

The extent to which COVID-19 vaccination reduces transmission varies with vaccine type and SARS-CoV-2 strain

Researchers from the University of Oxford have been examining the impact of vaccination on the spread of the Alpha and Delta variants through the population.

1 Oct 2021

No excess mortality during the Delta variant era in US state with high vaccination rates

Researchers have investigated the number of excess deaths during the initial spread of the Delta variant.

24 Sep 2021

Potential covalent SARS-CoV-2 spike protein inhibitors

There remains a significant need for new and effective drugs that can be used to treat COVID-19.

23 Sep 2021

COVID-19 deaths in U.S. surpass 1918 Spanish Flu pandemic

The coronavirus disease (COVID-19) pandemic is most likely the deadliest outbreak in recent American history, exceeding the estimated deaths from the 1918 influenza pandemic.

21 Sep 2021

Phase I trial investigates using antiparasitic nitazoxanide for treatment of COVID-19

In a recent study, researchers investigate the possibility of using the thiazolide antiparasitic nitazoxanide for the treatment of COVID-19.

15 Sep 2021

Impact of colloidal aggregation in COVID-19 drug repurposing screens

A recent study investigated the influence of colloidal aggregation on early drug development in repurposing screens

3 Sep 2021

First pharmacological treatment option for patients with a severe form of epilepsy

Epilepsy comes in a variety of forms. Those affected by a genetically de- termined variety have severe epileptic seizures as early as the first year of life.

1 Sep 2021

Existing drugs block or reduce SARS-CoV2 infection in cells

Since the beginning of the pandemic, researchers worldwide have been looking for ways to treat COVID-19. And while the COVID-19 vaccines represent the best measure to prevent the disease, therapies for those who do get infected remain in short supply.

19 Aug 2021

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

A new study has explored a series of potential flavonoid inhibitors targeting 3CL protease of SARS-CoV.

9 Aug 2021

New compound inspired by tapeworm drugs shows two-pronged effectiveness against COVID-19

A group of medications long prescribed to treat tapeworm has inspired a compound that shows two-pronged effectiveness against COVID-19 in laboratory studies, according to a new publication appearing online in the journal ACS Infectious Disease.

9 Aug 2021

Inhibition of SARS-CoV-2 replication in vitro by Losartan

A new study explores the use of Losartan to provide protection against COVID-19 pathogenesis.

3 Aug 2021

Finding potential microRNAs from humans and plants against SARS-CoV-2

A new study focuses on the identification of probable miRNA candidates from three medicinal plants.

1 Aug 2021

Scientist explore conserved RNA elements as potential targets for anti-SARS-CoV-2 drugs

The study, published in the journal Angewandte Chemie International Edition, identified many small molecules that bind to certain parts of the SARS-CoV-2 genome that are less likely altered by mutations using dedicated substance libraries. The scientists derived key functional units and groups in ligands for effective and safe targeting of SARS-CoV-2 RNA.

22 Jul 2021

COVID-19 researchers review 184 drug repurposing candidates

New research describes the use of integrative bioinformatics analyses of transcriptomic profiles for COVID-19 therapeutics.

15 Jul 2021

Repurposed drugs for COVID-19 treatment identified through virtual screening and cell-based assays

A joint research group from KAIST and Institut Pasteur Korea has identified repurposed drugs for COVID-19 treatment through virtual screening and cell-based assays.

8 Jul 2021

Discovery of SARS-CoV-2–induced pathways uncovers groundbreaking drug repurposing strategies

A new study has been published in Science Advances that exploits proteomics datasets to develop an agnostic network for SARS-CoV-2–induced pathways, thereby unveiling novel targets and potential repurposing strategies.

7 Jul 2021

Plant compounds inhibit Mpro of SARS-CoV-2 and HCoV-229E in vitro

A group of researchers recently discussed their findings that a group of plant flavonols and dihydroflavonols exhibit antiviral efficacy against both SARS-CoV-2 and HCoV-229E.

6 Jul 2021

CRISPRa identifies potassium channels as neuronal entry factors and druggable targets for SARS-CoV-2

New research led by Le Cong of Stanford University School of Medicine in California indicates that the KCNA6 potassium channel may help with viral entry and promote infection. In addition, KCNA6 is highly expressed in OLIG2+ neuronal cells, which has been shown to be suspectable to SARS-CoV-2 in the olfactory neuroepithelium. This area appears to contribute to loss of smell commonly observed during infection.